Why the study?
Antiarrhythmic drugs and catheter ablation for refractory VT can be associated with inadequate therapeutic responses and procedure-related complications.
Does stereotactic body radiotherapy (SBRT) provide a safe and effective alternative treatment for patients with refractory ventricular tachycardia?
Does stereotactic body radiotherapy (SBRT) provide a safe and effective alternative treatment for patients with refractory ventricular tachycardia?
Stereotactic body radiotherapy (SBRT) is emerging as a potential alternative treatment with a favorable safety profile for refractory ventricular tachycardia.
SBRT may be considered for refractory VT after failed ablation or drugs; leaves open the need for prospective trials before broader adoption.
Refractory ventricular tachycardia (VT) often occurs in the context of organic heart disease. It is associated with significantly high mortality and morbidity rates. Antiarrhythmic drugs and catheter ablation represent the two main treatment options for refractory VT, but their use can be associated with inadequate therapeutic responses and procedure-related complications. Stereotactic body radiotherapy (SBRT) is extensively applied in the precision treatment of solid tumors, with excellent therapeutic responses. Recently, this highly precise technology has been applied for radioablation of VT, and its early results demonstrate a favorable safety profile. This review presents the potential value of SBRT in refractory VT.
No takes yet. Share an insight, caveat, or question.
Shangguan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: